Browse diseases

…rs targeting CD70 show early promising results for their use in RCC in preclinical and clinical trials. However, further research a…

…umour and immune adaptation during ICI therapy in patients with advanced RCC reported opposing findings where responder tumours showed incre…

…ts We performed a multimodal analysis of 46 ICI-treated primary RCC tumour specimens from 33 patients, including 13 matched pretrea…

…cell-cell interactions among a cohort of primary breast cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, and RCC specimens. Putative tumor …

…nd in combination with pembrolizumab, across heavily pretreated advanced solid tumors in the ARTISTRY-1 study. We report in-depth antitumor activity,…

…ed CD8 + T cells to tumor cells contributes to immune escape of renal cell carcinoma (RCC), representing a major challenge in current immunotherapy.…

…ted renal cell carcinoma (RCC) is the most prevalent hereditary RCC and exhibits clinical heterogeneity, complicating patient manag…

…esponse to ICIs (p=0.7) (figure 1E). In patients with localized ccRCC undergoing nephrectomy, circulating plasma GDF-15 levels decrea…

…revolutionized treatment outcomes for advanced cancers, notably melanoma, NSCLC, RCC, urothelial carcinoma, and HNSCC. 1 2 By antagonizi…

…hausted CTL population (CD8+PD1+); the target for nivolumab, in CRC (n=4), RCC (n=2) and CaBr (n=3), Nivolumab treatment induced in…

…-h cough frequency supports further investigation of NAL ER for RCC.…

…s might improve outcome for a broader spectrum of patients with cancer. Phosphoantigen-responsive Vγ9Vδ2-T cells are potent immune cel…